[HTML][HTML] A multicenter retrospective study on the prognosis of stage III unresectable mutant non-small cell lung cancer with tyrosine kinase inhibitors therapy
R Wu, S Yu, J Ye, Y Wang, Z Zhao, H Liu… - Frontiers in …, 2021 - frontiersin.org
Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
R Wu, S Yu, J Ye, Y Wang, Z Zhao… - Frontiers in …, 2021 - pubmed.ncbi.nlm.nih.gov
Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
R Wu, S Yu, J Ye, Y Wang, Z Zhao… - … of Targeted Therapy …, 2022 - books.google.com
Background: For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
[HTML][HTML] A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy
R Wu, S Yu, J Ye, Y Wang, Z Zhao, H Liu… - Frontiers in …, 2021 - ncbi.nlm.nih.gov
Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
[PDF][PDF] A Multicenter Retrospective Study on the Prognosis Of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy …
R Wu, S Yu, J Ye, Y Wang, Z Zhao, H Liu, Y Song - Oncol, 2021 - core.ac.uk
Background: For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy.
R Wu, S Yu, J Ye, Y Wang, Z Zhao, H Liu… - Frontiers in …, 2021 - europepmc.org
Background For unresectable stage III non-small cell lung cancer (NSCLC), concurrent
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …
chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC …